Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 1 / Phase 2	2026-09-04		NCT05315700

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
ORIC Pharmaceuticals	4

42 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	131
Catholic University of Korea, St, Vincent Hospital	Gyeonggi-do	South Korea	1
Chris O'Brien Lifehouse	Camperdown	Australia	5
Chungbuk University Hospital	Cheongju-si	South Korea	1
City of Hope	Huntington Beach	United States	1
City of Hope	Irvine	United States	9
City of Hope	Duarte	United States	238
City of Hope	Long Beach	United States	3
Dana Farber Cancer Institute	Boston	United States	300
Duke Cancer Institute	Durham	United States	47
Gachon University Hospital	Incheon	South Korea	1
Georgetown University	Washington D.C.	United States	38
Hospital Kuala Lumpur	Kuala Lumpur	Malaysia	6
Mayo Clinic	Rochester	United States	664
Mayo Clinic	Jacksonville	United States	122
Medical University of Gdańsk	Gdansk	Poland	5
Moffitt Cancer Center	Tampa	United States	523
National Cancer Center	Goyang-si	South Korea	23
National Taiwan University Hospital	Taipei	Taiwan	203
NEXT Oncology	Fairfax	United States	31
NEXT Oncology - Barcelona	Barcelona	Spain	1
NEXT Oncology - Madrid	Madrid	Spain	1
Northwestern University	Chicago	United States	727
NYU Langone Health Perlmutter Cancer Center	New York	United States	8
One Clinical Research, Hollywood Medical Centre	Nedlands	Australia	1

Clinical trials